| High rates of forward transmission events after acute/early HIV-1 infection BG Brenner, M Roger, JP Routy, D Moisi, M Ntemgwa, C Matte, JG Baril, ... The Journal of infectious diseases 195 (7), 951-959, 2007 | 878 | 2007 |
| A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors B Brenner, D Turner, M Oliveira, D Moisi, M Detorio, M Carobene, ... Aids 17 (1), F1-F5, 2003 | 365 | 2003 |
| Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance S Spira, MA Wainberg, H Loemba, D Turner, BG Brenner Journal of Antimicrobial Chemotherapy 51 (2), 229-240, 2003 | 330 | 2003 |
| HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture BG Brenner, M Oliveira, F Doualla-Bell, DD Moisi, M Ntemgwa, F Frankel, ... Aids 20 (9), F9-F13, 2006 | 277 | 2006 |
| Development of antiretroviral drug resistance MA Wainberg, GJ Zaharatos, BG Brenner New England Journal of Medicine 365 (7), 637-646, 2011 | 266 | 2011 |
| Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection BG Brenner, JP Routy, M Petrella, D Moisi, M Oliveira, M Detorio, B Spira, ... Journal of virology 76 (4), 1753-1761, 2002 | 264 | 2002 |
| Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use H Salomon, MA Wainberg, B Brenner, Y Quan, D Rouleau, P Coté, ... Aids 14 (2), F17-F23, 2000 | 233 | 2000 |
| Whole-genome sequencing reveals host factors underlying critical COVID-19 A Kousathanas, E Pairo-Castineira, K Rawlik, A Stuckey, CA Odhams, ... Nature 607 (7917), 97-103, 2022 | 218 | 2022 |
| HIV drug resistance against strand transfer integrase inhibitors K Anstett, B Brenner, T Mesplede, MA Wainberg Retrovirology 14, 1-16, 2017 | 211 | 2017 |
| Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection B Brenner, JP Routy, Y Quan, D Moisi, M Oliveira, D Turner, MA Wainberg Aids 18 (12), 1653-1660, 2004 | 151 | 2004 |
| Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT H Loemba, B Brenner, MA Parniak, S Ma'ayan, B Spira, D Moisi, ... Antimicrobial agents and chemotherapy 46 (7), 2087-2094, 2002 | 145 | 2002 |
| Transmission networks of drug resistance acquired in primary/early stage HIV infection BG Brenner, M Roger, DD Moisi, M Oliveira, I Hardy, R Turgel, H Charest, ... Aids 22 (18), 2509-2515, 2008 | 143 | 2008 |
| High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens F Doualla-Bell, A Avalos, B Brenner, T Gaolathe, M Mine, S Gaseitsiwe, ... Antimicrobial agents and chemotherapy 50 (12), 4182-4185, 2006 | 138 | 2006 |
| Transmission clustering drives the onward spread of the HIV epidemic among men who have sex with men in Quebec BG Brenner, M Roger, D Stephens, D Moisi, I Hardy, J Weinberg, R Turgel, ... Journal of Infectious Diseases 204 (7), 1115-1119, 2011 | 136 | 2011 |
| Natural killer cell function in patients with acquired immunodeficiency syndrome and related diseases BG Brenner, A Dascal, RG Margolese, MA Wainberg Journal of Leukocyte Biology 46 (1), 75-83, 1989 | 117 | 1989 |
| Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations HT Xu, EL Asahchop, M Oliveira, PK Quashie, Y Quan, BG Brenner, ... Journal of virology 85 (21), 11300-11308, 2011 | 115 | 2011 |
| Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions B Brenner, MA Wainberg, M Roger Aids 27 (7), 1045-1057, 2013 | 108 | 2013 |
| Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1 D Coutsinos, CF Invernizzi, H Xu, D Moisi, M Oliveira, BG Brenner, ... Journal of virology 83 (4), 2029-2033, 2009 | 106 | 2009 |
| Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir M Oliveira, RI Ibanescu, K Anstett, T Mésplède, JP Routy, MA Robbins, ... Retrovirology 15, 1-14, 2018 | 97 | 2018 |
| Antiretroviral drug resistance in human immunodeficiency virus type 2 ML Ntemgwa, TA Toni, BG Brenner, RJ Camacho, MA Wainberg Antimicrobial agents and chemotherapy 53 (9), 3611-3619, 2009 | 96 | 2009 |
